( August 17, 2026, 03:25 GMT | Official Statement) -- MLex Summary: China’s Shaanxi Administration for Market Regulation urged active pharmaceutical ingredient companies to strengthen Antimonopoly compliance across production, sales, purchasing and merger activities, the provincial regulator said in a statement on Friday. More than 50 representatives from industry associations and companies attended the training session covering China’s Antimonopoly Law, pharmaceutical-sector Antimonopoly guidelines, risks involving monopoly agreements and abuse of dominance, and corporate compliance systems. Participants signed an industry Antimonopoly self-discipline commitment after the training and pledged to conduct regular compliance checks.Statement follows (in Chinese)....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.